Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum + pemetrexed + atezolizumab with or without bevacizumab in oncogene-driven advanced non-squamous NSCLC after targeted therapy
2019-000727-41Phase 2Active
- Sponsor
- Centre François Baclesse
- Start
- Jul 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, pemetrexed, carboplatin, cisplatin and bevacizumab in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Centre François Baclesse. Primary endpoint: Objective response rate. Started Jul 2019; status: active.
02
Drugs
atezolizumabpemetrexedcarboplatincisplatinbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2019-000727-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000727-41.